Skip to main content
. 2017 Sep 11;19:106. doi: 10.1186/s13058-017-0899-1

Table 1.

Characteristics of the patients that concluded the study

Characteristic Value
Number of included patients 46
Age, mean (range), years 54 (33–72)
Postmenopausal, n (%) 20 43
Histological assessment, n (%)
 Invasive ductal carcinoma 40 87
 Invasive lobular carcinoma 4 9
 Metaplastic carcinoma 2 4
TNM stage at diagnosis, n (%)
 T2N0 13 28
 T2N+ 17 37
 T3N0 5 11
 T3N+ 9 20
 T4N+ 2 4
Molecular characteristics, n (%)
 Luminal A 3 6
 Luminal B 16 35
 Luminal B HER2+ 6 13
 HER2+ 9 20
 Triple negative 12 26
Histopathological response to NAC in surgical specimen (RECIST 1.1), n (%)
 Complete response (pCR) 8 17
 Partial response (pPR) 32 70
 Stable disease (pSD) 5 11
 Progressive disease (pPD) 1 2
Surgical treatment, n (%)
 Lumpectomy 28 61
 Mastectomy 18 39

HER2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy, RECIST response evaluation criteria in solid tumors, pCR pathological complete response, pPR pathological partial response, pSD pathological stable disease, pPD pathological progressive disease